Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 24, 2019

View Archived Issues

PDC-CA4A-109 shows antitumor activity in breast and colon cancer models

MYCN-targeting antigene peptide oligonucleotide inhibits growth of MYCN-amplified neuroblastoma

Extension study results evaluating safety and effectiveness of dasotraline in binge-eating disorders

Maternal Zika vaccination protects macaque pregnancies

Jazz Pharmaceuticals enrolling patients in phase II/III study of JZP-458 for ALL/LBL

Gilead evaluates GS-6207 with other antiretrovirals for HIV in new phase II study

IL-1beta as a promising new biomarker in treatment-resistant bipolar depression

Interim data from gene therapy trial confirm BCL11A as therapeutic target in SCD

Lumateperone approved in the U.S. for schizophrenia

Trial to evaluate Trevena's TRV-734 for opioid use disorder

Phase II study begins for URO-902 in overactive bladder

PET imaging agent PyL meets primary endpoint in phase III prostate cancer trial

Phase I study of mutant EGFR inhibitor TQB-3804 begins

Celgene presents results from two phase I studies of CC-90002

CAPELLA trial recruits patients with HIV to evaluate add-on lenacapavir treatment

FDA approves first trial of ST-001 nanoFenretinide in T-cell non-Hodgkin's lymphoma

ABL Bio describes new anti-B7-H3 antibodies

Ubrogepant approved by the FDA for migraine

Lankenau Institute for Medical Research patents anti-rabies antibodies

New anti-OX40 antibodies synthesized at BeiGene

Apros Therapeutics discovers TLR7 peptide conjugates

Metastatic melanoma is targetable with lactate transport inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...